DRUG INDEX

Drug
Ceftriaxone

MOA
3rd generation cephalosphorin;
arrests bacterial growth by binding to
1 or more penicillin binding proteins,
thereby, in turn, inhibiting final
transpeptidation step of
peptidoglycan synthesis in bacterial
cell-wall synthesis and inhibiting cellwall biosynthesis
Inhibits cell-wall synthesis by binding
to penicillin-binding proteins; resistant
to most beta-lactamases

Indication
Broad-spectrum gram-negative
activity, including Pseudomonas

Dosage
50mg/kg IV every 12 hours

Adverse effect
Eosinophilia, thrombocytosi
diarrhea, elevated hepatic
transaminases, leukopenia,

Broad-spectrum gram-negative
activity, including Pseudomonas;
resistant to most betalactamases

20mg/kg IV q8hrs

Constipation, diarrhea, naus

vomiting, rash, headache,
inflammation at injection sit
sepsis

Vancomycin

Inhibits cell-wall biosynthesis; blocks

glycopeptide polymerization by
binding tightly to D-alanyl-D-alanine
portion of cell wall precursor

Broad-spectrum gram-negative
activity, including Pseudomonas;
resistant to most betalactamases

15mg/kg/day IV q8hrs

Chills, drug fever, eosinophi

rash, fatigue, peripheral ede
urinary tract infection, back
headache, reversible
neutopenia, phlebitis

Salbutamol

Beta 2 receptor agonist with some

beta1 activity, relaxes bronchial
smooth muscle with little effect on
heart rate

Used in treatment and

prevention of bronchospasm

0.2-0.6 mg/kg/day divided q46hrs

Nausea, fever, vomiting,

headache, dizziness, cough,
allergic reactions

Meropenem

Drug
Ceftazidime

Oxacillin

Amikacin

Penicillin G

Salbutamol

MOA
3rd generation
cephalosphorin; arrests
bacterial growth by binding to
1 or more penicillin binding
proteins, thereby, in turn,
inhibiting final
transpeptidation step of
peptidoglycan synthesis in
bacterial cell-wall synthesis
and inhibiting cell-wall
biosynthesis
Inhibits cell wall synthesis by
binding to one or more of the
penicillin binding proteins

Indication
Broad-spectrum gramnegative activity,
including Pseudomonas

Dosage
30mg/kg IV every 12
hours

Adverse effect
Transient increase in
transaminases,
eosinophilia, diarrhea,
hypersensitivity, phlebitis,
rash (maculopapular and
erythematous),
thrombocytosis

Used in treatment of
infections caused by
penicillinase-producing
staphylococci

Diarrhrea, nausea, fever,

rash

Irreversibly binds to 30s

subunit of bacterial
ribosomes; blocks recognition
step in protein synthesis;
causes growth inhibition
Interferes with cell wall
mucopeptide synthesis during
active multiplication, resulting
in bactericidal activity against
susceptible microorganisms

For gram-negative
bacterial coverage of
infections resistant to
gentamicin and
tobramycin
Broad-spectrum grampositive microorganisms

(<7 days old, <2kg) or

(>7 days old, <1.2kg):
50mg/kg/day divided q12
hours IV/IM
(<7 days old, >2kg) or
(>7 days old, 1.2kg-2kg):
75mg/kg/day divided q12
hours IV/IM
>7 days old, >2kg:
100mg/kg/day divided q6
hours IV/IM
34weeks gestational
age: 15mg/kg IV/IM
q24hr
50mg/kg IV every 12
hours

Skin rashes, urticaria,

Jarisch-Herxheimer
reaction,
pseudomembranous
colitis

Beta 2 receptor agonist with

some beta1 activity, relaxes
bronchial smooth muscle with
little effect on heart rate

Used in treatment and

prevention of
bronchospasm

0.2-0.6 mg/kg/day
divided q4-6hrs

Nausea, fever, vomiting,

headache, dizziness,
cough, allergic reactions

Neurotoxicity,
nephrotoxicity, ototoxicity

Hydrocortisone

Glucocorticoid, elicits mild

mineralocorticoid activity and
moderate anti-inflammatory
effects; controls or prevents
inflammation by controlling
rate of protein synthesis

Anti-inflammation

1-5 mg/kg/day IV divided

q 12-24hrs

Adrenal suppression,
arthralgia, bladder
dysfunction,
cardiomegaly, cushings
syndrome, delayed
wound healing, delirium,
epistaxis, fat embolism,
hirsutism, hyperglycemia,
hypokalemic alkalosis,
increased appetite,
indigestion, malaise